IMCAS Academy

Introduction
Program
Speakers
Sponsor list
Accreditation

IMCAS World Congress 2016
Program

FOCUS ON SESSION 21

Medical affairs - Safety of stem cell treatments

Room: Room 7
Date: Thursday 28 January 2016 at 11:00 to 12:00
Format: FOCUS SESSION > lectures covering a major topic of the congress

Chairs

Prof Guy MAGALON

Plastic Surgeon

France

Prof Foad NAHAI

Plastic Surgeon

United States

Lectures of the session

Hours	Speakers	Lecture title	Abstract	Number
11:00	Mathias KLUEMPER	Bringing stem-cell therapies to the patient - a European roadshow	View	29058
11:10	Prof Leihong Flora XIANG	The current situation of stem cell cosmetic application in Asia		29060
11:20	Prof Florence SABATIER	Risk management of ATMPs prepared under the "hospital exemption"		37542
11:30	Dr Pin Chi CHIU	Stem cell cosmetics in Asia - truth and hype	View	29064
11:40	John K FRASER	Assessing the safety of adipose-derived cell products: perspectives from a company developing products in both the EU and USA	View	29062
11:50		Questions & answers		29066

Go to previous session

Go to next session

Recommended sessions

Stem cells

Regulations & legal issues

Practice management & marketing

Mathias KLUEMPER

Lawyer

Germany

Other author(s) :

Bringing stem-cell therapies to the patient - a European roadshow

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Prof Leihong Flora XIANG

Dermatologist

China

Other author(s) :

The current situation of stem cell cosmetic application in Asia

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Prof Florence SABATIER

Plastic Surgeon

France

Other author(s) :

Risk management of ATMPs prepared under the "hospital exemption"

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Dr Pin Chi CHIU

Dermatologist

Taiwan

Other author(s) :

Stem cell cosmetics in Asia - truth and hype

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

John K FRASER

Industry Representative

United States

Other author(s) :

Assessing the safety of adipose-derived cell products: perspectives from a company developing products in both the EU and USA

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): CYTORI THERAPEUTICS

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: CYTORI THERAPEUTICS

Questions & answers

You have a question?

Quickly find your answer in our FAQ

Congresses

IMCAS Americas
IMCAS Asia
IMCAS World Congress

About

Company
Privacy Policy
Legal information

Academy

Home
Courses
Webinars
Explore
Blog

Grant

Educational grant

Get in touch

Username/Email

Password

Keep me logged in

Forgot password ? Do not have an account yet? Sign up now

Keep me logged in

academy.Do_not_have_an_account_yet Sign up now

IMCAS World Congress 2016 Program

FOCUS ON SESSION 21

Medical affairs - Safety of stem cell treatments

Chairs

Lectures of the session

Recommended sessions

IMCAS World Congress 2016
Program